64 min listen
Reshma L. Mahtani, DO - A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update…
Reshma L. Mahtani, DO - A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update…
ratings:
Length:
64 minutes
Released:
Mar 11, 2024
Format:
Podcast episode
Description
This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/IPCE information, and to apply for credit, please visit us at PeerView.com/MVX865. CME/MOC/NCPD/IPCE credit will be available until March 4, 2025.A Clinical Compass for Selecting and Sequencing HER2-Targeting Therapies in HER2-Positive Metastatic Breast Cancer: An Update on the Latest Evidence, Guidelines, and Expert Insights In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Daiichi Sankyo, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerReshma L. Mahtani, DO, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Agendia; Amgen Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Eisai Inc.; Genentech, Inc.; Gilead Sciences, Inc.; Hologic, Inc.; Lilly; Merck and Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; Sanofi; Seagen Inc.; Sermonix Pharmaceuticals; and Stemline Therapeutics, Inc.Grant/Research Support from AstraZeneca and Gilead Sciences, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.
Released:
Mar 11, 2024
Format:
Podcast episode
Titles in the series (100)
Anthony R. Mato, MD, MSCE - Interprofessional Perspectives on Safety Management With Targeted Therapy for B-Cell Malignancies: Go online to PeerView.com/ECV860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. by PeerView Internal Medicine CME/CNE/CPE Audio Podcast